

SKYEPHARMA PLC
Form 6-K
November 14, 2006

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

SkyePharma PLC

SKYEPHARMA APPOINTS NEW FINANCE DIRECTOR

LONDON, ENGLAND, 13 November 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces today down as Finance Director with immediate effect and will be leaving the Company to pursue a new has been appointed Finance Director in his place.

Peter, 51, is a Chartered Accountant with a MA (Hons), Mathematics from Oxford University. Marwick, Mitchell & Co. in 1979. With over 25 years of finance and management experience in U listed company board level, Peter brings extensive experience as a Finance Director at Molin Electron PLC where he worked as Group Finance Director until January 2005. Most recently, Commerce Group, a position he held until May 2006.

Donald joined SkyePharma in February 1996 and was appointed Finance Director in March 1997.

Jerry Karabelas, Chairman of SkyePharma, said:

"On behalf of the whole Board and staff, I would like to thank Donald for his significant contr over the past ten years. We wish him well for the future.

"We are very pleased to have recruited someone of Peter's calibre to fill the key role of significant role in streamlining operations, developing new business activities and financi management team of Frank Condella, CEO and Ken Cunningham, COO and will be of great assistance this important stage in its development."

Disclosure under section 9.6.13 of the Listing Rules:

Mr Grant resigned from the board of Eurodis Electron PLC in January 2005 for family health reasons gave notice of termination of its relationship with the group, and in July 2005 the lead finan the company went into administration.

There are no other disclosures under section 9.6.13 of the Listing Rules.

For further information please contact:

SkyePharma PLC

Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer

Buchanan Communications

Tim Anderson / Mark Court / Rebecca Skye Dietrich

The Trout Group
Seth Lewis

Notes for editors

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery te and more effective drug formulations. There are now eleven approved products incorporating Skye oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabi www.skyepharma.com.

Certain statements in this news release are forward-looking statements and are made in reliance U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio statements are reasonable, it can give no assurance that these expectations will materialize. B risks and uncertainties, actual results may vary significantly from those expressed or impli

Edgar Filing: SKYEPHARMA PLC - Form 6-K

based upon a number of factors, which are described in SkyePharma's 20-F and other documents on cause differences between actual results and those implied by the forward-looking statements c without limitation, risks related to the development of new products, risks related to obtaining for existing, new or expanded indications of existing and new products, risks related to SkyePh on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability maintain or expand market share in the face of changes in customer requirements, competition an to regulatory compliance, the risk of product liability claims, risks related to the ownership risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga forward-looking statement to reflect events or circumstances after the date of this release.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: November 14, 2006